ASH 2019 | Promising results for blinatumomab in younger relapsed B-ALL
Patrick Brown, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, discusses the late-breaking abstract data on the phase 3 trial (AALL1331; NCT02101853) of blinatumomab for the treatment of relapsed B-cell acute lymphoblastic leukemia (B-ALL). This trial studies how well blinatumomab works compared with standard combination chemotherapy in children and adolescents/young adults. Blinatumomab demonstrated superior efficacy and tolerability as post-reinduction consolidation prior to HSCT, resulting in higher rates of MRD response, greater likelihood of proceeding to HSCT and improved disease-free and overall survival. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
